Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nadim Ahmed | M | 56 | 3 years | |
| Sandra Leung | F | 63 | 32 years | |
| Stephen Webster | M | 63 | 4 years | |
| Anne-Marie Martin | M | 52 | 2 years | |
| Kimberly McCutcheon Jablonski | F | - | 21 years | |
| Robert Kerrey | M | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 years |
| Jeffrey Jones | M | 53 | 2 years | |
| William Perhacs | M | - | 17 years | |
| Tim Power | M | - | 18 years | |
| Jay Smith | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 11 years |
| Jay Skyler | M | 77 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 years |
| Sunita Zalani | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 10 years |
| Nancy Thornberry | F | 67 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 11 years |
| Kevin Johnston | M | - | 2 years | |
| Stephen Andre | M | 62 | 2 years | |
| Patrick Hugh Conway | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 years |
| Chad Messer | M | - | 2 years | |
| Rose Weldon | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Giovanni Caforio | M | 59 | 24 years | |
| Owen Hughes | M | 49 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 8 years |
| Lamberto Andreotti | M | 73 | 19 years | |
| Peter R. Dolan | M | 68 | 18 years | |
| Maria E. Cantor | F | 56 | - | |
| Charles A. Heimbold | M | - | 20 years | |
| James Cornelius | M | 81 | 10 years | |
| Daniel M. Bollag | M | 63 | 11 years | |
| Matthew Ros | M | 57 | 20 years | |
| James Ahlers | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 17 years |
| Douglas Manion | M | 64 | 11 years | |
| Massimo Radaelli | M | 65 | 8 years | |
| Michael Williams | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 years |
| Joseph Squicciarino | M | 67 | 22 years | |
| Priya Jambhekar | F | - | 3 years | |
| Steven B. Ratoff | M | 81 | 16 years | |
| Gerald Bruce | M | 68 | 8 years | |
| Norbert Riedel | M | 66 | 6 years | |
| Wayne L. Wilson | M | 75 | 8 years | |
| Brian Daniels | M | 65 | 14 years | |
| Togo Dennis West | M | 81 | 10 years | |
| David Spellman | M | 48 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 years |
| Mark W. Durand | M | 64 | 17 years | |
| Robert Whelan | M | 72 | 4 years | |
| David J. Helfgott | M | - | - | |
| John E. Elicker | M | 64 | 20 years | |
| John Tsai | M | 57 | 11 years | |
| Leif Valdemar Johansson | M | 73 | 13 years | |
| Laurie A. Allen | F | 63 | 9 years | |
| Rosemary Crane | F | 64 | 20 years | |
| Harrison Bains | M | 80 | 16 years | |
| Fouad Namouni | M | 55 | 21 years | |
| Charles Sigal | M | 72 | 16 years | |
| Anthony Hooper | M | 69 | 15 years | |
| Louis J. Freeh | M | 74 | 8 years | |
| Lawrence Hamilton | M | 66 | 8 years | |
| Timothy Meeker | M | 77 | 13 years | |
| Jeffrey Trigilio | M | 40 | 4 years | |
| Jon Wigginton | M | 62 | 2 years | |
| A. Collier Smyth | M | 78 | 15 years | |
| Barry J. Wolfenson | M | 57 | 23 years | |
| Robert Williams | M | 75 | 7 years | |
| James Robinson | M | 88 | 29 years | |
| Michael Grobstein | M | 81 | 13 years | |
| Alan J. Lacy | M | 70 | 12 years | |
| Louis Gerstner | M | - | - | |
| Laurie Glimcher | M | 72 | 20 years | |
| Lewis B. Campbell | M | 77 | 18 years | |
| Vicki Sato | M | 75 | 15 years | |
| Jason Haddock | M | 54 | 14 years | |
| Luisa Salter-Cid | M | 60 | 13 years | |
| Vladimir Coric | M | 53 | 8 years | |
| Robert Berman | M | 61 | 10 years | |
| John Shamsey | M | - | 6 years | |
| Mark Neumann | M | 61 | 26 years | |
| Dolca Thomas | M | 53 | 4 years | |
| Robert E. Allen | M | - | 21 years | |
| J. Brian Stalter | M | 52 | 11 years | |
| Steve Innaimo | M | - | 23 years | |
| James Daniel Guylain Priour | M | 57 | - | |
| Rachel Humphrey | M | 62 | 9 years | |
| George Zavoico | M | - | - | |
| Paul von Autenried | M | 62 | 26 years | |
| Adeoye Olukotun | M | 79 | 13 years | |
| William T. Comer | M | 85 | 9 years | |
| John F. Bedard | M | 74 | - | |
| Carlo de Notaristefani | M | 67 | 7 years | |
| Richard L. Wolgemuth | M | 78 | - | |
| Brian M. Gallagher | M | 76 | - | |
| R. Jean-Marc Sidney Huët | M | 55 | 1 years | |
| Michael Loberg | M | 76 | 18 years | |
| Nancy Lurker | F | 66 | 14 years | |
| Michelle Werner | F | 48 | 10 years | |
| Philippe Deschamps | M | 62 | 12 years | |
| Dinesh Patel | M | 67 | 8 years | |
| Charles Rowland | M | 65 | 8 years | |
| David J. Franklin | M | - | - | |
| Stacey M. Lituchy | F | - | - | |
| Julie Smith | F | 53 | - | |
| Marcel Giguère | M | - | 7 years | |
| Axel Hoos | M | 54 | 6 years | |
| Allison Luo | M | 50 | 8 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Raymond T. Keane
- Personal Network
